In short
Clinical trials are studying 2-DEOXY-D-GLUCOSE in healthy adults to see whether it can help prevent rhinovirus-associated illness. These trials focus on how well it works compared with placebo, and they also look at safety and other study outcomes.
Key points
- One clinical trial studied 2-DEOXY-D-GLUCOSE in healthy adults to see if it could prevent rhinovirus-associated illness. It was a Phase 2 interventional study and used placebo as the comparison treatment. The trial enrolled 128 people and has been completed. The main outcome was the difference in the rate of rhinovirus-associated illness between 2-DEOXY-D-GLUCOSE and placebo. The study used a controlled human rhinovirus infection design, which means volunteers were studied under careful control after virus exposure.
Trial overview
This article covers one clinical trial of 2-DEOXY-D-GLUCOSE in healthy adults with a focus on rhinovirus-associated illness. The study title describes it as a controlled human rhinovirus infection study, and the brief summary says it was done to confirm whether 2-DEOXY-D-GLUCOSE worked better than placebo for prevention.
The trial was Phase 2, which means it was designed to look more closely at whether the study treatment may work in a specific group of people. It was also an interventional study, meaning the researchers gave a study treatment and compared the results with another group.
Study design and treatment groups
The study compared 2-DEOXY-D-GLUCOSE with placebo. A placebo is a look-alike treatment with no active study drug, used so results can be compared fairly.
The intervention list shows a placebo group and a 2-DEOXY-D-GLUCOSE group given as a nasal spray at 56 mg. The trial was completed and enrolled 128 people.
Who participated
The study enrolled healthy adults. In clinical trials, healthy adults are often chosen when the goal is to test prevention, because they do not already have the target illness at the start of the study.
The condition being studied was rhinovirus-associated illness, which is illness linked to rhinovirus infection. This type of study helps researchers observe whether the treatment can reduce the chance of getting sick after controlled virus exposure.
Main outcome measured
The primary outcome was the difference in the rate of rhinovirus-associated illness between 2-DG and placebo. A primary outcome is the main result the researchers planned to measure to answer the study question.
This outcome shows that the main aim was to find out whether 2-DEOXY-D-GLUCOSE could help prevent illness better than placebo in this study setting.
What this trial adds
This completed Phase 2 trial adds early clinical evidence about 2-DEOXY-D-GLUCOSE for prevention of rhinovirus-associated illness in healthy adults. Because the study was controlled and compared with placebo, it was set up to give a clearer answer about whether the treatment changed illness rates.
The available trial data do not show results in this source, so the main information here is about the study question, the population, the phase, and the outcome being measured.